Second-generation antiepileptic medications in children: efficacy and cognitive effects

References

• Camfield P, Camfield C, Smith S, Dooley J, Smith E. Long-term outcome is unchanged by antiepileptic drug treatment after a first seizure: a 15-year follow-up from a randomized trial in childhood. Epilepsia 43, 662–663 (2002).
   Google Scholar
• Birbeck GL, Hays RD, Cui X, Vickrey BG. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 43, 535–538 (2002).
   PubMed Web of Science ®Google Scholar
• Report of the ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 39, 799–803 (1998).
   Google Scholar
• Begley CE, Heaney DC. Economic evaluation of epilepsy treatment: a review of the literature. Epilepsia 43 (Suppl. 4), 10–17 (2002).
   Google Scholar
• ••Review of the methodologies for assessingthe costs of monotherapy and add-on therapy.
   Google Scholar
• Matson AG, Chadwick DW. New drug treatments for epilepsy. J: Neural. Neumsurg. Psychiatry70, 143–155 (2001).
   Google Scholar
• Glauser TA. Expanding first-line therapy options for children with partial seizures. Neurology55 (Suppl. 3), S30—S37 (2002).
   Google Scholar
• Arunkumar G, Wyllie E, Kotagal P, Ong HT, Gilliam E Parent and patient validated content for pediatric quality-of-life. Epilepsia 41, 1474–1484 (2000).
   Google Scholar
• Mattson RII, Cramer JA, Collins JF et al Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic — clonic seizures. N Engl. I Merl 1313, 145–151 (1985).
   Google Scholar
• Mattson RII, Cramer JA, Collins JF and the Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic — clonic seizures in adults. N Engl. Merl 1327, 765–771 (1992).
   Google Scholar
• Rochat P, Hallas J, Gaist D, Friis ML. Antiepileptic drug utilization: a Danish prescription database analysis. Acta Neural. Scary/. 104,6–11 (2001).
   Google Scholar
• Lindberger M, Alenius M, Frisén L eta]. Gabapentin in refractory epilepsy add-on treatment. Epilepsia 41,1289–1295 (2000).
   Google Scholar
• Steiner TJ, Dellaportas CI, Findley LJ eta]. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 40,601–607 (1999).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 345,476–479 (1995).
   Google Scholar
• Brodie MJ, Overstall PW, Giorgi L, the UK Elderly Study Group. Lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res. 37, 81–87 (1999).
   Google Scholar
• Reunanen M, Dam M, Yuen AWC. A randomized open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res. 23,149–155 (1996).
   Google Scholar
• Nieto-Barrera M, Brozmanova M, Capovilla G eta]. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res. 46, 145–55 (2001).
   Google Scholar
• Guerreiro MM, Vigonius U, Pohlmann H eta] A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 27,205–213 (1997).
   PubMed Web of Science ®Google Scholar
• Bill PA, Vigonius U, Pohlmann H eta] A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 27,195–204 (1997).
   PubMed Web of Science ®Google Scholar
• Reinikainen KJ, Keranen T, Halonen T, Komulainen H, Riekkinen PJ. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res. 1,284–289 (1987).
   PubMed Web of Science ®Google Scholar
• Dam M, Ekberg R, Loyning Y, Waltimo 0, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 3,70-76 (1989).
   Google Scholar
• Christe W, Kramer G, Vigonius U eta]. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 26,451–460 (1997).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl. I Med. 342, 314–319 (2000).
   PubMed Web of Science ®Google Scholar
• •The paper to read, with important observations including that the new drugs may not be adding much to our ability to make patients seizure free. Clearly, this approach will need to be constantly updated as even newer drugs are increasingly used. Also important is the finding that persons not responding to the first AEDs probably have something quite wrong with their brain and the chances of becoming seizure free with any drug are small. Indirectly supports the argument for early surgical intervention.
   Google Scholar
• Lhatoo SD, Wong ICK, Polizzi G, Sander JWAS. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 41,1592–1596 (2000).
   PubMed Web of Science ®Google Scholar
• Meador KJ, Gilliam FG, Kanner AM, Pellock JM. Cognitive and behavioral effects of antiepileptic drugs. Epilepsy Behav. 2, SS1—SS17 (2001).
   Google Scholar
• Bourgeois BFD. Antiepileptic drugs, learning, and behavior in childhood epilepsy. Epilepsia 39,913–921 (1998).
   Google Scholar
• Baker GA, Hesdon B, Matson AG. Quality-of-life and behavioral measures in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards. Epilepsia 41, 1357–1363 (2000).
   PubMed Web of Science ®Google Scholar
• ••A study performed about studies.Randomized-controlled trials of AEDs were reviewed to evaluate the methodologies used for assessing mood and quality of life. Concerns are expressed regarding the validity of the measures in the epilepsy population and failure to review previously defined methods, 52 different exams were used in 46 trials.
   Google Scholar
• Leach JP, Girvan J, Paul A, Brodie MJ. Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J. Neural. Neurosurg. By& 62,372–376 (1997).
   PubMed Web of Science ®Google Scholar
• Meador KJ, Loring DW, Ray PG eta]. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 40,1279–1285 (1999).
   Google Scholar
• Martin R, Meador K, Turrentine L eta]. Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults. Epilepsia 42,764–771 (2001).
   Google Scholar
• Salinsky MC, Binder LM, Okin BS, Storzbach D, Aron CR, Dodrill CB. Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers. Epilepsia 43,482–490 (2002).
   PubMed Web of Science ®Google Scholar
• Smith D, Baker G, Dewey M, Chadwick DW Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 34, 312–322 (1993).
   PubMed Web of Science ®Google Scholar
• •The investigators address an interesting problem that arises in many double-blind studies, can the patients and investigators really remain blinded? True placebo effects are well known to occur but certainly many drugs produce significant effects on seizures, mood, or just not feeling well. The investigators actually studied how accurate the guesses were.
   Google Scholar
• Gillham R, Kane K, Bryant-Comstock L, Brodie MJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 9,375–379 (2000).
   Google Scholar
• ••The authors use a modified Side Effectand Life Satisfaction (SEALS) inventory a self-report questionnaire to follow their patients. Interestingly, serial testing showed the major change early and this might allow for other interventions at the onset of the study to either alter drug dosing or supplement care to maintain subjects in long-term study.
   Google Scholar
• Meador KJ, Loring DW, Ray PG etal. Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neumlogy56, 1177–1182 (2001).
   Google Scholar
• ••This study is not unique its use of normalpaid volunteers to assess the effects of a medication. The methodology of which tools are used in assessing the impact of the AEDs, however, rivals the best of any study. Many of the tasks have previously been demonstrated to be sensitive to these effects and a detailed description is provided.
   Google Scholar
• Aldenkamp AP, Arends J, Bootsma HPR et al. Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 43, 19–26 (2002).
   PubMedGoogle Scholar
• Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. j Autism and Dev. Disord. 31,175-181 (2001).
   Google Scholar
• •Not an important study regarding the impact of LTG on autism. However, the observation that parents report significant improvement in spite of objective studies not demonstrating changes raises questions regarding reports of medication side effects in drug trials, or perhaps the ability of standardized tests to demonstrate what they purport to do.
   Google Scholar
• Cramer JA, Arrigo C, Van Hammée G, Gauer LJ, Cereghino JJ, for the N132 Study Group. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 41, 868–874 (2000).
   Google Scholar
• Neyens LGJ, Alpherts WCJ, Aldenkamp AR Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Pmg. Neuro-PFchopharmacol. Biol. fiychiat. 19,411–419 (1995).
   PubMed Web of Science ®Google Scholar
• Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur. j Gun. Pharmacol 44,529–533 (1993).
   Google Scholar
• Aikia M, Kalviainen R, Sivenius J, Halonen T, Riekkinen PJ. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res. 11,199–203 (1992).
   PubMed Web of Science ®Google Scholar
• Dodrill CB, Arnett JL, Sommerville KW, Shu V. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 48, 1025–1031 (1997).
   Google Scholar
• Dodrill CB, Arnett JL, Shu V, Pixton GC, Lenz GT, Sommerville KW Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 39,33–42 (1998).
   PubMedGoogle Scholar
• Dodrill CB, Arnett JL, Deaton R, Lenz GT, Sommerville KW Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood. Epilepsy Res. 42,123–132 (2000).
   PubMed Web of Science ®Google Scholar
• Cramer J, Ryan J, Chang J, Sommerville K, M92-825 Study Group. The short-term impact of adjunctive tiagabine on health-related quality of life. Epilepsia 42 (Suppl. 3), 70–75 (2001).
   Google Scholar
• Elterman RD, Glauser TA, Wyllie E eta]. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology52, 1338–1344 (1999).
   Google Scholar
• Aldenkamp AP, Baker G, Mulder OG eta]. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 41, 1167–1178 (2000).
   Google Scholar
• Martin R, Kuzniecky R, Ho S et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 52,321–327 (1999).
   PubMed Web of Science ®Google Scholar
• Greenwood RS. Adverse effects of antiepileptic drugs. Epilepsia 41\(Suppl. 2), S42—S52 (2000).
   Google Scholar
• Glauser TA. Idiosyncratic reactions: new methods of identifying high-risk patients.Epilepsia 41 (Suppl. 8), S16—S29 (2000).
   Google Scholar
• Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherpy in patients with epilepsy. Neurology56, 172–177 (2001).
   PubMed Web of Science ®Google Scholar
• Genton P, Bauer J, Duncan S et al. On the association between valproate and polycystic ovary syndrome. Epilepsia 42, 295–304 (2001).
   PubMed Web of Science ®Google Scholar
• Isojärvi JIT, Tauboll E, Tapanainen JS eta]. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia 42,305–310 (2001).
   Google Scholar
• Penovich PE. The effects of epilepsy and its treatment on sexual and reproductive function. Epilepsia 41 (Suppl. 2), S53—S61 (2000).
   Google Scholar
• Rattya J, Turkka J, Pakarinen AJ eta]. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neumlogy 56,31–36 (2001).
   Google Scholar
• Guo C-Y, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 42,1141–1147 (2001).
   Google Scholar
• Ferrendelli JA. Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy. Epilepsia 42 (Suppl. 4), 28 (2001).
   Google Scholar
• •Brief review of the data supporting introduction rates of both new and older AEDs.
   Google Scholar
• Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 49,542–546 (1997).
   PubMed Web of Science ®Google Scholar
• Guberman AH, Besag FMC, Brodie MJ etal. Lamotrigine-associated rash: risk/ benefit considerations in adults and children. Epilepsia 40,985–991 (1999).
   PubMed Web of Science ®Google Scholar
• Matson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 38, 859–880 (1997).
   Google Scholar
• ••Start of the detailed mathematical analysesto allow comparison of all the AEDs and in conjunction with [59] all new approved medications are included. A list of the studies included is provided and this serves as the starting point for other investigators' approaches.
   Google Scholar
• Privitera MD. Evidence-based medicine and antiepileptic drugs. Epilepsia 40 (Suppl 5), S47—S56 (1999).
   Google Scholar
• Marson AG, Hutton JL, Leach JP eta]. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res. 46,259–270 (2001).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 40,590–600 (1999).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Ben Menachem EB, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res. 47,17–25 (2001).
   PubMedGoogle Scholar
• Elferink JA, Van Zwieten-Boot BJ. New antiepileptic drugs. Analysis based on number needed to treat shows differences between drugs studied. BE Med. J. 314, 603 (1997).
   Google Scholar
• van Rijckevorsel K. The 'number needed to treat' with levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs). Seizure10, 235–236 (2001).
   Google Scholar
• Lesaffre E, Boon P, Pledger GW. The value of the number-needed-to-treat method in antiepileptic drug trials. Epilepsia 41,440–446 (2000).
   Google Scholar
• •After-the-fact paper that explains [62] and [63]. The methodology is explained in detail and contrasted to OR determinations, the advantage of the number-to-treat for the clinician, but the concerns expressed by the statisticians. Includes an example using TPX.
   Google Scholar
• Brodie MJ. Lamotrigine versus other antiepileptic drugs: a star rating system is born. Epilepsia 35 (Suppl. 5), S41—S46 (1994).
   Google Scholar
• Karceski S, Morrell M, Carpenter D. The expert consensus guideline series. Treatment of epilepsy. Epilepsy Behavior 2, A1—A50 (2001).
   Google Scholar
• Wilcox KS. Developing new drugs for intractable epilepsy and preventing epilepsy. Innovative epilepsy therapies for the 21st century. American Epilepsy Society Meeting, Philadelphia, PA, USA, November 30 — December 5 (2001).
   Google Scholar
• ••Review and insight into what is necessaryto move the development of new medications foreward.
   Google Scholar
• purling MJ, Symes CVV, Lawlor PA et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 287, 1453–1460 (2000). Adeno-associated virus-delivered vaccine is provided to rats with subsequent antibodies generated which are protective for up to 1–5 months in kainic-induced seizures and middle cerebral artery occlusion induced stroke. Is everyone vaccinated at birth?
   Google Scholar